Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Veru Inc VERU

Consumer Defensive Household & Personal Products
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed in two different programs... see more

Recent & Breaking News (NDAQ:VERU)

Veru to Report Fiscal 2019 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 12th

GlobeNewswire December 5, 2019

Veru Announces Full Enrollment of Phase 2 Trial in Men with Prostate Cancer Treatment Induced Hot Flashes

GlobeNewswire October 2, 2019

Veru to Participate at Three Upcoming Healthcare Investor Conferences in New York

GlobeNewswire August 28, 2019

Veru to Ring NASDAQ Closing Bell on September 4th to Kick Off National Prostate Cancer Awareness Month

GlobeNewswire August 27, 2019

Veru Reports Higher Net Revenues and Gross Profit for its Fiscal 2019 Third Quarter

GlobeNewswire August 8, 2019

Veru to Report Fiscal 2019 Third-Quarter Financial Results; Host Conference Call on August 8th

GlobeNewswire August 1, 2019

Veru Announces Dismissal of Lawsuit; Prevails on All Counts in Motion for Summary Judgment

GlobeNewswire July 18, 2019

Veru Announces Successful Completion of Pre-NDA Meeting with FDA for TADFIN (Tadalafil 5mg and Finasteride 5mg) Combination for the Treatment of Benign Prostatic Hyperplasia

GlobeNewswire June 26, 2019

Veru Adds Breakthrough Novel Androgen Deprivation Therapy Formulation to its Advancing Prostate Cancer Drug Pipeline Following Successful Meeting with FDA

GlobeNewswire June 4, 2019

Veru to Present at the Jefferies 2019 Global Healthcare Conference on June 4th

GlobeNewswire May 28, 2019

Veru Reports Strong Fiscal 2019 Second-Quarter Financial Results

GlobeNewswire May 15, 2019

Veru to Report Fiscal 2019 Second-Quarter Financial Results; Host Conference Call on May 15th

GlobeNewswire May 8, 2019

Veru to Participate in Two Investor Conferences in March

GlobeNewswire March 12, 2019

Veru Reports Strong Fiscal 2019 First Quarter Financial Results

GlobeNewswire February 13, 2019

Veru Announces Scientific Presentations for Novel Prostate Cancer Drug Candidates at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium

GlobeNewswire February 12, 2019

Veru to Report Fiscal 2019 First-Quarter Financial Results, Host Conference Call on February 13th

GlobeNewswire February 6, 2019

Veru Initiates Clinical Trial for Proprietary, Novel, First-in-Class Drug for Advanced Prostate Cancer

GlobeNewswire January 22, 2019

Veru Announces Acceptance of Four Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2019

GlobeNewswire January 15, 2019

Veru Announces Successful Bioavailability and Bioequivalence Clinical Trial for Tadalafil and Finasteride Combination Tablet for Benign Prostatic Hyperplasia

GlobeNewswire January 14, 2019

Veru Reports Strong Net Revenues and Gross Profit for Fiscal 2018 Fourth-Quarter

GlobeNewswire December 13, 2018